Exploration of Targeted Anti-tumor Therapy

Table 2. Chemosensitizing potential of PL

Drugs	Cancer	**In vitro/In vivo**	Model	Mechanism	References
Bortezomib	MM	In vitro	NCI-H929	↑Apoptosis, ↓p-STAT3	[110]
Cisplatin	HNC	In vitro	AMC-HN2, -HN3, -HN4, -HN6, -HN7, -HN8, SNU-1041, -1066, -1076, HN30, HN31, UMSCC1, 93-VU-147T	↑ROS, ↓GSH, ↑GSSG, ↑PUMA, ↑cleaved PARP, ↑p-JNK, ↓GSTP1, -HN9, ↑p-p53 (Ser 15), ↑apoptosis	[149]
Cisplatin	HNC	In vivo	AMC-HN2 & -HN9, xenograft	↓Tumor growth, ↑p53, ↑apoptosis	[149]
Doxorubicin	Prostate cancer	In vitro	DU-145	↑Apoptosis, ↑caspase-3, ↑cleaved PARP	[148]
5-Flurouracil	Oral cancer	In vitro	SAS, CGHNC8	↓Cell viability, ↓survival	[144]
Gemcitabine	Pancreatic cancer	In vitro	BxPC-3, PANC-1, AsPC-1	↑Apoptosis, ↓NF-κB	[115]
Gemcitabine	Pancreatic cancer	In vivo	BxPC-3 xenograft	↓Tumor burden, ↑apoptosis, ↓NF-κB	[115]
Oxaliplatin	Gastric cancer	In vitro	SGC-7901, AGS, BGC-823	↓TrxR1 activity, ↑ROS, ↑apoptosis, Activation of p38 and JNK signaling pathways, ↑γ-H2A.X	[147]
Oxaliplatin	Gastric cancer	In vivo	SGC-7901 xenograft	↓Tumor growth, ↓TrxR1 activity	[147]
PTX	Intestinal Cancer	In vitro	INT-407 and HCT-116	↓Proliferation	[127]

Return to article view

GSSG: GSH disulphide; p: phosphorylated

Declarations

Acknowledgements

The authors acknowledge DBT-AIST International Center for Translational and Environmental Research (DAICENTER) for providing support to carry out the present work.

Author contributions

ABK contributed to the study design, conceptualisation, supervision and review editing. DP and VR performed bibliographic search. DP and SG contributed to original manuscript. DP and VR contributed to table preparation and proofreading. AK and DP performed artwork. DP, SG, UDD, EV and KKT contributed to review editing. DP, SG, AK and UDD contributed to proofreading.

Conflicts of interest

The authors express no conflict of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This project was supported by DBT-AIST International Center for Translational and Environmental Research (DAICENTER). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Banik K, Harsha C, Bordoloi D, Lalduhsaki Sailo B, Sethi G, Leong HC, et al. Therapeutic potential of gambogic acid, a caged xanthone, to target cancer. Cancer Lett. 2018;416:75–86. [DOI] [PubMed]

Banik K, Ranaware AM, Deshpande V, Nalawade SP, Padmavathi G, Bordoloi D, et al. Honokiol for cancer therapeutics: a traditional medicine that can modulate multiple oncogenic targets. Pharmacol Res. 2019;144:192–209. [DOI] [PubMed]

Banik K, Ranaware AM, Harsha C, Nitesh T, Girisa S, Deshpande V, et al. Piceatannol: a natural stilbene for the prevention and treatment of cancer. Pharmacol Res. 2020;153:104635. [DOI] [PubMed]

Girisa S, Shabnam B, Monisha J, Fan L, Halim CE, Arfuso F, et al. Potential of zerumbone as an anti-cancer agent. Molecules. 2019;24:734. [DOI]

Khwairakpam AD, Bordoloi D, Thakur KK, Monisha J, Arfuso F, Sethi G, et al. Possible use of Punica granatum (Pomegranate) in cancer therapy. Pharmacol Res. 2018;133:53–64. [DOI] [PubMed]

Ranaware AM, Banik K, Deshpande V, Padmavathi G, Roy NK, Sethi G, et al. Magnolol: a neolignan from the magnolia family for the prevention and treatment of cancer. Int J Mol Sci. 2018;19:2362. [DOI]

Roy NK, Deka A, Bordoloi D, Mishra S, Kumar AP, Sethi G, et al. The potential role of boswellic acids in cancer prevention and treatment. Cancer Lett. 2016;377:74–86. [DOI] [PubMed]

Sailo BL, Banik K, Girisa S, Bordoloi D, Fan L, Halim CE, et al. FBXW7 in cancer: what has been unraveled thus far? Cancers (Basel). 2019;11:246. [DOI]

Sailo BL, Banik K, Padmavathi G, Javadi M, Bordoloi D, Kunnumakkara AB. Tocotrienols: the promising analogues of vitamin E for cancer therapeutics. Pharmacol Res. 2018;130:259–72. [DOI] [PubMed]

10.

Shabnam B, Padmavathi G, Banik K, Girisa S, Monisha J, Sethi G, et al. Sorcin a potential molecular target for cancer therapy. Transl Oncol. 2018;11:1379–89. [DOI] [PubMed] [PMC]

11.

Bordoloi D, Roy NK, Monisha J, Padmavathi G, Kunnumakkara AB. Multi-targeted agents in cancer cell chemosensitization: what we learnt from curcumin thus far. Recent Pat Anticancer Drug Discov. 2016;11:67–97. [DOI] [PubMed]

12.

Bordoloi D, Sailo BL, Manteghi N, Padmavathi G, Kunnumakkara AB. Introduction and basic concepts of cancer. In: Kunnumakkara AB, Bordoloi D, Monisha J, editor. Cancer cell chemoresistance and chemosensitization. Singapore: World Scientific; 2018. pp. 1–13. [DOI]

13.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. [DOI] [PubMed]

14.

Khatoon E, Banik K, Harsha C, Sailo BL, Thakur KK, Khwairakpam AD, et al. Phytochemicals in cancer cell chemosensitization: current knowledge and future perspectives. Semin Cancer Biol. 2020;S1044-579X:30150-4. [DOI]

15.

Singh AK, Roy NK, Bordoloi D, Padmavathi G, Banik K, Khwairakpam AD, et al. Orai-1 and Orai-2 regulate oral cancer cell migration and colonisation by suppressing Akt/mTOR/NF-kappaB signalling. Life Sci. 2020;261:118372. [DOI] [PubMed]

16.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Pineros M, Znaor A, et al. Cancer statistics for the year 2020: an overview. Int J Cancer. 2021;[Epub ahead of print]. [DOI]

17.

Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, Lai OS, et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res. 2008;25:2097–116. [DOI] [PubMed] [PMC]

18.

Aggarwal BB, Sethi G, Baladandayuthapani V, Krishnan S, Shishodia S. Targeting cell signaling pathways for drug discovery: an old lock needs a new key. J Cell Biochem. 2007;102:580–92. [DOI] [PubMed]

19.

Shanmugam MK, Lee JH, Chai EZ, Kanchi MM, Kar S, Arfuso F, et al. Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds. Semin Cancer Biol. 2016;40–41:35–47. [DOI]

20.

Kunnumakkara AB, Bordoloi D, Sailo BL, Roy NK, Thakur KK, Banik K, et al. Cancer drug development: the missing links. Exp Biol Med (Maywood). 2019;244:663–89. [DOI] [PubMed] [PMC]

21.

Henamayee S, Banik K, Sailo BL, Shabnam B, Harsha C, Srilakshmi S, et al. Therapeutic emergence of rhein as a potential anticancer drug: a review of its molecular targets and anticancer properties. Molecules. 2020;25:2278. [DOI]

22.

Kirtonia A, Gala K, Fernandes SG, Pandya G, Pandey AK, Sethi G, et al. Repurposing of drugs: an attractive pharmacological strategy for cancer therapeutics. Semin Cancer Biol. 2021;68:258–78. [DOI] [PubMed]

23.

Kunnumakkara AB. Anticancer properties of fruits and vegetables. Singapore: World Scientific; 2015.

24.

Nair AS, Shishodia S, Ahn KS, Kunnumakkara AB, Sethi G, Aggarwal BB. Deguelin, an Akt inhibitor, suppresses IkappaBalpha kinase activation leading to suppression of NF-kappaB-regulated gene expression, potentiation of apoptosis, and inhibition of cellular invasion. J Immunol. 2006;177:5612–22. [DOI] [PubMed]

25.

Khanna D, Sethi G, Ahn KS, Pandey MK, Kunnumakkara AB, Sung B, et al. Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol. 2007;7:344–51. [DOI] [PubMed]

26.

Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. Cancer Res. 2007;67:3853–61. [DOI] [PubMed]

27.

Kunnumakkara AB, Nair AS, Ahn KS, Pandey MK, Yi Z, Liu M, et al. Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-kappaB activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis. Blood. 2007;109:5112–21. [DOI] [PubMed] [PMC]

28.

Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, et al. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets. Int J Cancer. 2012;131:E292–303. [DOI] [PubMed] [PMC]

29.

Quinn BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, Hollander MC, et al. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila). 2013;6:801–10. [DOI] [PubMed] [PMC]

30.

Padmavathi G, Rathnakaram SR, Monisha J, Bordoloi D, Roy NK, Kunnumakkara AB. Potential of butein, a tetrahydroxychalcone to obliterate cancer. Phytomedicine. 2015;22:1163–71. [DOI] [PubMed]

31.

Padmavathi G, Roy NK, Bordoloi D, Arfuso F, Mishra S, Sethi G, et al. Butein in health and disease: a comprehensive review. Phytomedicine. 2017;25:118–27. [DOI] [PubMed]

32.

Kunnumakkara AB, Banik K, Bordoloi D, Harsha C, Sailo BL, Padmavathi G, et al. Googling the guggul (commiphora and boswellia) for prevention of chronic diseases. Front Pharmacol. 2018;9:686. [DOI] [PubMed] [PMC]

33.

Bordoloi D, Monisha J, Roy NK, Padmavathi G, Banik K, Harsha C, et al. An investigation on the therapeutic potential of butein, a tretrahydroxychalcone against human oral squamous cell carcinoma. Asian Pac J Cancer Prev. 2019;20:3437–46. [DOI] [PubMed] [PMC]

34.

Roy NK, Parama D, Banik K, Bordoloi D, Devi AK, Thakur KK, et al. An update on pharmacological potential of boswellic acids against chronic diseases. Int J Mol Sci. 2019;20:4101. [DOI]

35.

Zhang YJ, Gan RY, Li S, Zhou Y, Li AN, Xu DP, et al. Antioxidant phytochemicals for the prevention and treatment of chronic diseases. Molecules. 2015;20:21138–56. [DOI] [PubMed] [PMC]

36.

Kunnumakkara AB, Chung JG, Koca C, Dey S. Mint and its constituents. In: Kunnumakkara AB, Aggarwal BB, editor. Molecular targets and therapeutic uses of spices. 2009; pp. 373–401.

37.

Kunnumakkara AB, Sung B, Ravindran J, Diagaradjane P, Deorukhkar A, Dey S, et al. γ-Tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Res. 2010;70:8695–705. [DOI] [PubMed] [PMC]

38.

Gutierrez RMP, Gonzalez AMN, Hoyo-Vadillo C. Alkaloids from piper: a review of its phytochemistry and pharmacology. Mini Rev Med Chem. 2013;13:163–93. [DOI] [PubMed]

39.

Palombo EA. Phytochemicals from traditional medicinal plants used in the treatment of diarrhoea: modes of action and effects on intestinal function. Phytother Res. 2006;20:717–24. [DOI] [PubMed]

40.

Howes MJ, Perry E. The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging. 2011;28:439–68. [DOI] [PubMed]

41.

Ahmed SA, Parama D, Daimari E, Girisa S, Banik K, Harsha C, et al. Rationalizing the therapeutic potential of apigenin against cancer. Life Sci. 2021;267:118814. [DOI] [PubMed]

42.

Aswathy M, Banik K, Parama D, Sasikumar P, Harsha C, Joseph AG, et al. Exploring the cytotoxic effects of the extracts and bioactive triterpenoids from dillenia indica against oral squamous cell carcinoma: a scientific interpretation and validation of indigenous knowledge. ACS Pharmacol Transl Sci. 2021; 4:834–47. [DOI] [PubMed] [PMC]

43.

Babu BH, Jayram HN, Nair MG, Ajaikumar KB, Padikkala J. Free radical scavenging, antitumor and anticarcinogenic activity of gossypin. J Exp Clin Cancer Res. 2003;22:581–9. [PubMed]

44.

Aggarwal BB, Kunnumakkara AB, Harikumar KB, Tharakan ST, Sung B, Anand P. Potential of spice-derived phytochemicals for cancer prevention. Planta Med. 2008;74:1560–9. [DOI] [PubMed]

45.

Choudhury B, Kandimalla R, Bharali R, Monisha J, Kunnumakara AB, Kalita K, et al. Anticancer activity of garcinia morella on T-cell murine lymphoma via apoptotic induction. Front Pharmacol. 2016;7:3. [DOI] [PubMed] [PMC]

46.

Monisha J, Padmavathi G, Roy NK, Deka A, Bordoloi D, Anip A, et al. NF-κB blockers gifted by mother nature: prospectives in Cancer Cell Chemosensitization. Curr Pharm Des. 2016;22:4173–200. [DOI] [PubMed]

47.

Maruthanila VL, Elancheran R, Kunnumakkara AB, Kabilan S, Kotoky J. Recent development of targeted approaches for the treatment of breast cancer. Breast Cancer. 2017;24:191–219. [DOI] [PubMed]

48.

Kunnumakkara AB, Sailo BL, Banik K, Harsha C, Prasad S, Gupta SC, et al. Chronic diseases, inflammation, and spices: how are they linked? J Transl Med. 2018;16:14. [DOI] [PubMed] [PMC]

49.

Awasthee N, Rai V, Chava S, Nallasamy P, Kunnumakkara AB, Bishayee A, et al. Targeting IkappaappaB kinases for cancer therapy. Semin Cancer Biol. 2019;56:12–24. [DOI] [PubMed] [PMC]

50.

Buhrmann C, Popper B, Kunnumakkara AB, Aggarwal BB, Shakibaei M. Evidence that calebin A, a component of Curcuma Longa suppresses NF-B mediated proliferation, invasion and metastasis of human colorectal cancer induced by TNF-β (Lymphotoxin). Nutrients. 2019;11:2904. [DOI]

51.

Nair A, Amalraj A, Jacob J, Kunnumakkara AB, Gopi S. Non-curcuminoids from turmeric and their potential in cancer therapy and anticancer drug delivery formulations. Biomolecules. 2019;9:13. [DOI]

52.

Shu L, Cheung KL, Khor TO, Chen C, Kong AN. Phytochemicals: cancer chemoprevention and suppression of tumor onset and metastasis. Cancer Metastasis Rev. 2010;29:483–502. [DOI] [PubMed]

53.

Dias DA, Urban S, Roessner U. A historical overview of natural products in drug discovery. Metabolites. 2012;2:303–36. [DOI] [PubMed] [PMC]

54.

Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79:629–61. [DOI] [PubMed]

55.

Thomas D, Govindhan S, Baiju EC, Padmavathi G, Kunnumakkara AB, Padikkala J. Cyperus rotundus L. prevents non-steroidal anti-inflammatory drug-induced gastric mucosal damage by inhibiting oxidative stress. J Basic Clin Physiol Pharmacol. 2015;26:485–90. [DOI] [PubMed]

56.

Harsha C, Banik K, Bordoloi D, Kunnumakkara AB. Antiulcer properties of fruits and vegetables: a mechanism based perspective. Food Chem Toxicol. 2017;108:104–19. [DOI] [PubMed]

57.

Khwairakpam AD, Damayenti YD, Deka A, Monisha J, Roy NK, Padmavathi G, et al. Acorus calamus: a bio-reserve of medicinal values. J Basic Clin Physiol Pharmacol. 2018;292:107–22. [DOI]

58.

Devi Khwairakpam A, Monisha J, Roy NK, Bordoloi D, Padmavathi G, Banik K, et al. Vietnamese coriander inhibits cell proliferation, survival and migration via suppression of Akt/mTOR pathway in oral squamous cell carcinoma. J Basic Clin Physiol Pharmacol. 2019;31:20190162. [DOI]

59.

Parama D, Boruah M, Yachna K, Rana V, Banik K, Harsha C, et al. Diosgenin, a steroidal saponin, and its analogs: effective therapies against different chronic diseases. Life Sci. 2020;260:118182. [DOI] [PubMed]

60.

Chatterjee A, Dutta CP. Alkaloids of Piper longum Linn. I. Structure and synthesis of piperlongumine and piperlonguminine. Tetrahedron. 1967;23:1769–81. [DOI] [PubMed]

61.

Bezerra DP, Pessoa C, de Moraes MO, Saker-Neto N, Silveira ER, Costa-Lotufo LV. Overview of the therapeutic potential of piplartine (piperlongumine). Eur J Pharm Sci. 2013;48:453–63. [DOI] [PubMed]

62.

Tripathi SK, Biswal BK. Piperlongumine, a potent anticancer phytotherapeutic: perspectives on contemporary status and future possibilities as an anticancer agent. Pharmacol Res. 2020;156:104772. [DOI] [PubMed]

63.

Yadav V, Krishnan A, Vohora D. A systematic review on Piper longum L.: bridging traditional knowledge and pharmacological evidence for future translational research. J Ethnopharmacol. 2020;247:112255. [DOI] [PubMed]

64.

Zhang Q, Chen W, Lv X, Weng Q, Chen M, Cui R, et al. Piperlongumine, a novel TrxR1 inhibitor, induces apoptosis in hepatocellular carcinoma cells by ROS-mediated ER stress. Front Pharmacol. 2019;10:1180. [DOI] [PubMed] [PMC]

65.

Joshi K, Panara K, Nishteswar K, Chaudhary S. Cultivation and pharmacological profiles of root of Piper longum Linn. Pharma Science Monitor. 2013;4:3617–27.

66.

Choudhary N, Singh V. A census of P. longum’s phytochemicals and their network pharmacological evaluation for identifying novel drug-like molecules against various diseases, with a special focus on neurological disorders. PLoS One. 2018;13:e0191006. [DOI]

67.

Yan WJ, Wang Q, Yuan CH, Wang F, Ji Y, Dai F, et al. Designing piperlongumine-directed anticancer agents by an electrophilicity-based prooxidant strategy: a mechanistic investigation. Free Radic Biol Med. 2016;97:109–23. [DOI] [PubMed]

68.

Lad NP, Kulkarni S, Sharma R, Mascarenhas M, Kulkarni MR, Pandit SS. Piperlongumine derived cyclic sulfonamides (sultams): synthesis and in vitro exploration for therapeutic potential against HeLa cancer cell lines. Eur J Med Chem. 2017;126:870–8. [DOI] [PubMed]

69.

He K, Xu H, Wang T, Li X, Guo B, Li D, et al. An improved synthesis of piperlongumine and the preliminary imaging evaluation on tumor targeting. J Radioanal Nucl Chem. 2020;324:489–96. [DOI]

70.

Sun LD, Wang F, Dai F, Wang YH, Lin D, Zhou B. Development and mechanism investigation of a new piperlongumine derivative as a potent anti-inflammatory agent. Biochem Pharmacol. 2015;95:156–69. [DOI] [PubMed]

71.

Han LC, Stanley PA, Wood PJ, Sharma P, Kuruppu AI, Bradshaw TD, et al. Horner-Wadsworth-Emmons approach to piperlongumine analogues with potent anti-cancer activity. Org Biomol Chem. 2016;14:7585–93. [DOI] [PubMed]

72.

Li Q, Chen L, Dong Z, Zhao Y, Deng H, Wu J, et al. Piperlongumine analogue L50377 induces pyroptosis via ROS mediated NF-kappaB suppression in non-small-cell lung cancer. Chem Biol Interact. 2019;313:108820. [DOI] [PubMed]

73.

D’Sousa Costa CO, Araujo Neto JH, Baliza IRS, Dias RB, Valverde LF, Vidal MTA, et al. Novel piplartine-containing ruthenium complexes: synthesis, cell growth inhibition, apoptosis induction and ROS production on HCT116 cells. Oncotarget. 2017;8:104367–92. [DOI] [PubMed] [PMC]

74.

Oliveira MS, Barbosa MIF, de Souza TB, Moreira DRM, Martins FT, Villarreal W, et al. A novel platinum complex containing a piplartine derivative exhibits enhanced cytotoxicity, causes oxidative stress and triggers apoptotic cell death by ERK/p38 pathway in human acute promyelocytic leukemia HL-60 cells. Redox Biol. 2019;20:182–94. [DOI] [PubMed] [PMC]

75.

Baliza IRS, Silva SLR, Santos LS, Neto JHA, Dias RB, Sales CBS, et al. Ruthenium complexes with piplartine cause apoptosis through MAPK signaling by a p53-dependent pathway in human colon carcinoma cells and inhibit tumor development in a xenograft model. Front Oncol. 2019;9:582. [DOI] [PubMed] [PMC]

76.

Gurumurthy P, Vijayalatha S, Sumathy A, Asokan M, Naseema M. Hepatoprotective effect of aqueous extract of Piper longum and piperine when administered with antitubercular drugs. The Bioscan. 2012;7:661–3.

77.

Khushbu C, Lalkrishna P, Roshni S, Virendra K, Dhaval M, Timir P. Effect of Piper longum Linn on histopathological and biochemical changes in isoproterenol induced myocardial infarction in rats. Res J Pharm Biol Chem Sci. 2010;1:759–66.

78.

Lee SE, Park BS, Huh TL, Lee EW, Yum JH. Proteomic evaluation on antiplatelet activity of piperlongumine derived from Piper longum. Mol cell Toxicol. 2010;6:295–303. [DOI]

79.

Rao VR, Muthenna P, Shankaraiah G, Akileshwari C, Babu KH, Suresh G, et al. Synthesis and biological evaluation of new piplartine analogues as potent aldose reductase inhibitors (ARIs). Eur J Med Chem. 2012;57:344–61. [DOI] [PubMed] [PMC]

80.

Son DJ, Kim SY, Han SS, Kim CW, Kumar S, Park BS, et al. Piperlongumine inhibits atherosclerotic plaque formation and vascular smooth muscle cell proliferation by suppressing PDGF receptor signaling. Biochem Biophys Res Commun. 2012;427:349–54. [DOI] [PubMed] [PMC]

81.

Felipe FCB, Sousa Filho JT, de Oliveira Souza LE, Silveira JA, de Andrade Uchoa DE, Silveira ER, et al. Piplartine, an amide alkaloid from Piper tuberculatum, presents anxiolytic and antidepressant effects in mice. Phytomedicine. 2007;14:605–12. [DOI] [PubMed]

82.

Mgbeahuruike EE, Stålnacke M, Vuorela H, Holm Y. Antimicrobial and synergistic effects of commercial piperine and piperlongumine in combination with conventional antimicrobials. Antibiotics. 2019;8:55. [DOI]

83.

Niu M, Xu X, Shen Y, Yao Y, Qiao J, Zhu F, et al. Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity. Chem Biol Interact. 2015;237:66–72. [DOI] [PubMed]

84.

Zhang Z, Wang F, Du C, Guo H, Ma L, Liu X, et al. BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling. Cancer Lett. 2017;402:213–24. [DOI] [PubMed]

85.

Dhillon H, Chikara S, Reindl KM. Piperlongumine induces pancreatic cancer cell death by enhancing reactive oxygen species and DNA damage. Toxicol Rep. 2014;1:309–18. [DOI] [PubMed] [PMC]

86.

Sethi G, Ahn KS, Sung B, Kunnumakkara AB, Chaturvedi MM, Aggarwal BB. SH-5, an AKT inhibitor potentiates apoptosis and inhibits invasion through the suppression of anti-apoptotic, proliferative and metastatic gene products regulated by IkappaBalpha kinase activation. Biochem Pharmacol. 2008;76:1404–16. [DOI] [PubMed]

87.

Roy NK, Bordoloi D, Monisha J, Padmavathi G, Kotoky J, Golla R, et al. Specific targeting of Akt kinase isoforms: taking the precise path for prevention and treatment of cancer. Curr Drug Targets. 2017;18:421–35. [DOI] [PubMed]

88.

Roy NK, Monisha J, Padmavathi G, Lalhruaitluanga H, Kumar NS, Singh AK, et al. Isoform-specific role of Akt in oral squamous cell carcinoma. Biomolecules. 2019;9:253. [DOI]

89.

Harsha C, Banik K, Ang HL, Girisa S, Vikkurthi R, Parama D, et al. Targeting AKT/mTOR in oral cancer: mechanisms and advances in clinical trials. Int J Mol Sci. 2020;21:3285. [DOI]

90.

Makhov P, Golovine K, Teper E, Kutikov A, Mehrazin R, Corcoran A, et al. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death. Br J Cancer. 2014;110:899–907. [DOI] [PubMed] [PMC]

91.

Seok JS, Jeong CH, Petriello MC, Seo HG, Yoo H, Hong K, et al. Piperlongumine decreases cell proliferation and the expression of cell cycle-associated proteins by inhibiting Akt pathway in human lung cancer cells. Food Chem Toxicol. 2018;111:9–18. [DOI] [PubMed]

92.

Liu Z, Shi Z, Lin J, Zhao S, Hao M, Xu J, et al. Piperlongumine-induced nuclear translocation of the FOXO3A transcription factor triggers BIM-mediated apoptosis in cancer cells. Biochem Pharmacol. 2019;163:101–10. [DOI] [PubMed]

93.

Gao F, Zhou L, Li M, Liu W, Yang S, Li W. Inhibition of ERKs/Akt-mediated c-Fos expression is required for piperlongumine-induced Cyclin D1 downregulation and tumor suppression in colorectal cancer cells. Onco Targets Ther. 2020;13:5591–603. [DOI] [PubMed] [PMC]

94.

Zhou L, Li M, Yu X, Gao F, Li W. Repression of hexokinases II-mediated glycolysis contributes to Piperlongumine-induced tumor suppression in non-small cell lung cancer cells. Int J Biol Sci. 2019;15:826–37. [DOI] [PubMed] [PMC]

95.

Wang F, Mao Y, You Q, Hua D, Cai D. Piperlongumine induces apoptosis and autophagy in human lung cancer cells through inhibition of PI3K/Akt/mTOR pathway. Int J Immunopathol Pharmacol. 2015;28:362–73. [DOI] [PubMed]

96.

Garg AK, Jhingran A, Klopp AH, Aggarwal BB, Kunnumakkara AB, Broadus RR, et al. Expression of nuclear transcription factor kappa B in locally advanced human cervical cancer treated with definitive chemoradiation. Int J Radiat Oncol Biol Phys. 2010;78:1331–6. [DOI] [PubMed] [PMC]

97.

Heymach JV, Shackleford TJ, Tran HT, Yoo SY, Do KA, Wergin M, et al. Effect of low-fat diets on plasma levels of NF-kappaB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila). 2011;4:1590–8. [DOI] [PubMed] [PMC]

98.

Monisha J, Roy NK, Bordoloi D, Kumar A, Golla R, Kotoky J, et al. Nuclear factor kappa B: a potential target to persecute head and neck cancer. Curr Drug Targets. 2017;18:232–53. [DOI] [PubMed]

99.

Kunnumakkara AB, Shabnam B, Girisa S, Harsha C, Banik K, Devi TB, et al. Inflammation, NF-κB, and chronic diseases: how are they linked? Crit Rev Immunol. 2020;40:1–39. [DOI] [PubMed]

100.

Jeong CH, Ryu H, Kim DH, Cheng WN, Yoon JE, Kang S, et al. Piperlongumine induces cell cycle arrest via reactive oxygen species accumulation and IKKβ suppression in human breast cancer cells. Antioxidants (Basel). 2019;8:553. [DOI]

101.

Ginzburg S, Golovine KV, Makhov PB, Uzzo RG, Kutikov A, Kolenko VM. Piperlongumine inhibits NF-kappaB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate. 2014;74:177–86. [DOI] [PubMed] [PMC]

102.

Zheng J, Son DJ, Gu SM, Woo JR, Ham YW, Lee HP, et al. Piperlongumine inhibits lung tumor growth via inhibition of nuclear factor kappa B signaling pathway. Sci Rep. 2016;6:26357. [DOI] [PubMed] [PMC]

103.

Aggarwal BB, Kunnumakkara AB. Molecular targets and therapeutic uses of spices. Singapore: World Scientific; 2009.

104.

Rawlings JS, Rosler KM, Harrison DA. The JAK/STAT signaling pathway. J Cell Sci. 2004;117:1281–3. [DOI] [PubMed]

105.

Bhutani M, Pathak AK, Nair AS, Kunnumakkara AB, Guha S, Sethi G, et al. Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation. Clin Cancer Res. 2007;13:3024–32. [DOI] [PubMed]

106.

Spitzner M, Ebner R, Wolff HA, Ghadimi BM, Wienands J, Grade M. STAT3: a novel molecular mediator of resistance to chemoradiotherapy. Cancers (Basel). 2014;6:1986–2011. [DOI] [PubMed] [PMC]

107.

Khanna P, Chua PJ, Bay BH, Baeg GH. The JAK/STAT signaling cascade in gastric carcinoma (review). Int J Oncol. 2015;47:1617–26. [DOI] [PubMed]

108.

Mullen M, Gonzalez-Perez RR. Leptin-induced JAK/STAT signaling and cancer growth. Vaccines (Basel). 2016;4:26. [DOI]

109.

Song B, Zhan H, Bian Q, Gu J. Piperlongumine inhibits gastric cancer cells via suppression of the JAK1,2/ STAT3 signaling pathway. Mol Med Rep. 2016;13:4475–80. [DOI] [PubMed]

110.

Yao Y, Sun Y, Shi M, Xia D, Zhao K, Zeng L, et al. Piperlongumine induces apoptosis and reduces bortezomib resistance by inhibiting STAT3 in multiple myeloma cells. Oncotarget. 2016;7:73497–508. [DOI] [PubMed] [PMC]

111.

Kim YH, Yoon YJ, Lee YJ, Kim CH, Lee S, Choung DH, et al. Piperlongumine derivative, CG-06, inhibits STAT3 activity by direct binding to STAT3 and regulating the reactive oxygen species in DU145 prostate carcinoma cells. Bioorg Med Chem Lett. 2018;28:2566–72. [DOI] [PubMed]

112.

Chen SY, Huang HY, Lin HP, Fang CY. Piperlongumine induces autophagy in biliary cancer cells via reactive oxygen species-activated Erk signaling pathway. Int J Mol Med. 2019;44:1687–96. [DOI] [PubMed] [PMC]

113.

Thongsom S, Suginta W, Lee KJ, Choe H, Talabnin C. Piperlongumine induces G2/M phase arrest and apoptosis in cholangiocarcinoma cells through the ROS-JNK-ERK signaling pathway. Apoptosis. 2017;22:1473–84. [DOI] [PubMed]

114.

Randhawa H, Kibble K, Zeng H, Moyer MP, Reindl KM. Activation of ERK signaling and induction of colon cancer cell death by piperlongumine. Toxicol In vitro. 2013;27:1626–33. [DOI] [PubMed] [PMC]

115.

Wang Y, Wu X, Zhou Y, Jiang H, Pan S, Sun B. Piperlongumine suppresses growth and sensitizes pancreatic tumors to gemcitabine in a xenograft mouse model by modulating the NF-kappa B pathway. Cancer Prev Res (Phila). 2016;9:234–44. [DOI] [PubMed]

116.

Sriwiriyajan S, Sukpondma Y, Srisawat T, Madla S, Graidist P. (-)-Kusunokinin and piperloguminine from Piper nigrum: an alternative option to treat breast cancer. Biomed Pharmacother. 2017;92:732–43. [DOI] [PubMed]

117.

Park JA, Na HH, Jin HO, Kim KC. Increased expression of FosB through reactive oxygen species accumulation functions as pro-apoptotic protein in Piperlongumine treated MCF7 breast cancer cells. Mol Cells. 2019;42:884–92. [DOI] [PubMed] [PMC]

118.

Tanida I, Ueno T, Kominami E. Human light chain 3/MAP1LC3B is cleaved at its carboxyl-terminal Met121 to expose Gly120 for lipidation and targeting to autophagosomal membranes. J Biol Chem. 2004;279:47704–10. [DOI] [PubMed]

119.

Duan C, Zhang B, Deng C, Cao Y, Zhou F, Wu L, et al. Piperlongumine induces gastric cancer cell apoptosis and G2/M cell cycle arrest both in vitro and in vivo. Tumour Biol. 2016;37:10793–804. [DOI] [PubMed]

120.

Delaney LM, Farias N, Ghassemi Rad J, Fernando W, Annan H, Hoskin DW. The natural alkaloid Piperlongumine inhibits metastatic activity and epithelial-to-mesenchymal transition of triple-negative mammary carcinoma cells. Nutr Cancer. 2020:1–14. [DOI]

121.

Park MJ, Lee DE, Shim MK, Jang EH, Lee JK, Jeong SY, et al. Piperlongumine inhibits TGF-beta-induced epithelial-to-mesenchymal transition by modulating the expression of E-cadherin, Snail1, and Twist1. Eur J Pharmacol. 2017;812:243–9. [DOI] [PubMed]

122.

Niu M, Shen Y, Xu X, Yao Y, Fu C, Yan Z, et al. Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF-kappaB p65 subunit nuclear import. Biochem Biophys Res Commun. 2015;462:326–31. [DOI] [PubMed]

123.

Liu D, Qiu XY, Wu X, Hu DX, Li CY, Yu SB, et al. Piperlongumine suppresses bladder cancer invasion via inhibiting epithelial mesenchymal transition and F-actin reorganization. Biochem Biophys Res Commun. 2017;494:165–72. [DOI] [PubMed]

124.

Ljepoja B, Garcia-Roman J, Sommer AK, Frohlich T, Arnold GJ, Wagner E, et al. A proteomic analysis of an in vitro knock-out of miR-200c. Sci Rep. 2018;8:6927. [DOI] [PubMed] [PMC]

125.

Karki K, Hedrick E, Kasiappan R, Jin UH, Safe S. Piperlongumine induces reactive oxygen species (ROS)-dependent downregulation of specificity protein transcription factors. Cancer Prev Res (Phila). 2017;10:467–77. [DOI] [PubMed] [PMC]

126.

Jin HO, Park JA, Kim HA, Chang YH, Hong YJ, Park IC, et al. Piperlongumine downregulates the expression of HER family in breast cancer cells. Biochem Biophys Res Commun. 2017;486:1083–9. [DOI] [PubMed]

127.

Rawat L, Hegde H, Hoti SL, Nayak V. Piperlongumine induces ROS mediated cell death and synergizes paclitaxel in human intestinal cancer cells. Biomed Pharmacother. 2020;128:110243. [DOI] [PubMed]

128.

Huang JR, Wang ST, Wei MN, Liu K, Fu JW, Xing ZH, et al. Piperlongumine alleviates mouse colitis and colitis-associated colorectal cancer. Front Pharmacol. 2020;11:586885. [DOI] [PubMed] [PMC]

129.

Wang H, Jiang H, Corbet C, de Mey S, Law K, Gevaert T, et al. Piperlongumine increases sensitivity of colorectal cancer cells to radiation: involvement of ROS production via dual inhibition of glutathione and thioredoxin systems. Cancer Lett. 2019;450:42–52. [DOI] [PubMed]

130.

Kumar S, Agnihotri N. Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer. Biomed Pharmacother. 2019;109:1462–77. [DOI] [PubMed]

131.

DA Silva Machado F, Munari FM, Scariot FJ, Echeverrigaray S, Aguzzoli C, Pich CT, et al. Piperlongumine induces apoptosis in colorectal cancer HCT 116 cells independent of bax, p21 and p53 status. Anticancer Res. 2018;38:6231–6. [DOI] [PubMed]

132.

Basak D, Punganuru SR, Srivenugopal KS. Piperlongumine exerts cytotoxic effects against cancer cells with mutant p53 proteins at least in part by restoring the biological functions of the tumor suppressor. Int J Oncol. 2016;48:1426–36. [DOI] [PubMed]

133.

Li W, Wen C, Bai H, Wang X, Zhang X, Huang L, et al. JNK signaling pathway is involved in piperlongumine-mediated apoptosis in human colorectal cancer HCT116 cells. Oncol Lett. 2015;10:709–15. [DOI] [PubMed] [PMC]

134.

Turkez H, Nobrega FRD, Ozdemir O, Bezerra Filho C, Almeida RN, Tejera E, et al. NFBTA: a potent cytotoxic agent against glioblastoma. Molecules. 2019;24:2411. [DOI]

135.

Zou P, Xia Y, Ji J, Chen W, Zhang J, Chen X, et al. Piperlongumine as a direct TrxR1 inhibitor with suppressive activity against gastric cancer. Cancer Lett. 2016;375:114–26. [DOI] [PubMed]

136.

Kim TH, Song J, Kim SH, Parikh AK, Mo X, Palanichamy K, et al. Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates ER stress, and preferentially kills high-grade glioma cells. Neuro Oncol. 2014;16:1354–64. [DOI] [PubMed] [PMC]

137.

Ye W, Huang Q, Tang T, Qin G. Synergistic effects of piperlongumine and gemcitabine against KRAS mutant lung cancer. Tumori. 2020;107:119–24. [DOI] [PubMed]

138.

Halas-Wisniewska M, Zielinska W, Izdebska M, Grzanka A. The synergistic effect of Piperlongumine and sanguinarine on the non-small lung cancer. Molecules. 2020;2:3045. [DOI]

139.

Mohammad J, Singh RR, Riggle C, Haugrud B, Abdalla MY, Reindl KM. JNK inhibition blocks piperlongumine-induced cell death and transcriptional activation of heme oxygenase-1 in pancreatic cancer cells. Apoptosis. 2019;24:730–44. [DOI] [PubMed] [PMC]

140.

Yamaguchi Y, Kasukabe T, Kumakura S. Piperlongumine rapidly induces the death of human pancreatic cancer cells mainly through the induction of ferroptosis. Int J Oncol. 2018;52:1011–22. [DOI] [PubMed]

141.

Song X, Gao T, Lei Q, Zhang L, Yao Y, Xiong J. Piperlongumine induces apoptosis in human melanoma cells via reactive oxygen species mediated mitochondria disruption. Nutr Cancer. 2018;70:502–11. [DOI] [PubMed]

142.

Hang W, Yin ZX, Liu G, Zeng Q, Shen XF, Sun QH, et al. Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1. Oncogene. 2018;37:3384–98. [DOI] [PubMed] [PMC]

143.

Gagat M, Halas-Wisniewska M, Zielinska W, Izdebska M, Grzanka D, Grzanka A. The effect of piperlongumine on endothelial and lung adenocarcinoma cells with regulated expression of profilin-1. Onco Targets Ther. 2018;11:8275–92. [DOI] [PubMed] [PMC]

144.

Chen YJ, Kuo CC, Ting LL, Lu LS, Lu YC, Cheng AJ, et al. Piperlongumine inhibits cancer stem cell properties and regulates multiple malignant phenotypes in oral cancer. Oncol Lett. 2018;15:1789–98. [DOI] [PubMed] [PMC]

145.

Chen SY, Liu GH, Chao WY, Shi CS, Lin CY, Lim YP, et al. Piperlongumine suppresses proliferation of human oral squamous cell carcinoma through cell cycle arrest, apoptosis and senescence. Int J Mol Sci. 2016;17:616. [DOI]

146.

Golovine K, Makhov P, Naito S, Raiyani H, Tomaszewski J, Mehrazin R, et al. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biol Ther. 2015;16:743–9. [DOI] [PubMed] [PMC]

147.

Zhang P, Shi L, Zhang T, Hong L, He W, Cao P, et al. Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells. Cell Oncol (Dordr). 2019;42:847–60. [DOI] [PubMed]

148.

Piska K, Koczurkiewicz P, Wnuk D, Karnas E, Bucki A, Wojcik-Pszczola K, et al. Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells-the involvement of carbonyl reductase 1 inhibition. Chem Biol Interact. 2019;300:40–8. [DOI] [PubMed]

149.

Roh JL, Kim EH, Park JY, Kim JW, Kwon M, Lee BH. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer. Oncotarget. 2014;5:9227–38. [DOI] [PubMed] [PMC]

150.

Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861–74. [DOI] [PubMed] [PMC]

151.

Roy NK, Sharma A, Singh AK, Bordoloi D, Sailo BL, Monisha J, et al. Bladder cancer: chemoresistance and chemosensitization. In: Cancer cell chemoresistance and chemosensitization. Singapore: World Scientific; 2018. pp. 51–80. [DOI]

152.

Oneda E, Abu Hilal M, Zaniboni A. Biliary tract cancer: current medical treatment strategies. Cancers (Basel). 2020;12:1237. [DOI]

153.

Grunnet M, Mau-Sorensen M. Serum tumor markers in bile duct cancer-a review. Biomarkers. 2014;19:437–43. [DOI] [PubMed]

154.

Kumar P, Bolshette NB, Jamdade VS, Mundhe NA, Thakur KK, Saikia KK, et al. Breast cancer status in India: an overview. Biomed Prev Nutr. 2013;3:177–83. [DOI]

155.

Thakur KK, Bordoloi D, Kunnumakkara AB. Alarming burden of triple-negative breast cancer in India. Clin Breast Cancer. 2018;18:e393–9. [DOI] [PubMed]

156.

Daimary UD, Parama D, Rana V, Banik K, Kumar A, Harsha C, et al. Emerging roles of cardamonin, a multitargeted nutraceutical in the prevention and treatment of chronic diseases. Curr Res Pharmacol Drug Discovery. 2021;2:100008. [DOI]

157.

Banik K, Sailo BL, Thakur KK, Jaiswal A, Monisha J, Bordoloi D, et al. Potential of different chemosensitizers to overcome chemoresistance in cervical cancer. In: Cancer cell chemoresistance and chemosensitization. Singapore: World Scientific; 2018. pp. 163–79. [DOI]

158.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. [DOI] [PubMed]

159.

Kunnumakkara AB, Guha S, Aggarwal BB. Curcumin and colorectal cancer: add spice to your life. Curr Colorectal Cancer Rep. 2009;5:5. [DOI]

160.

Araghi M, Soerjomataram I, Jenkins M, Brierley J, Morris E, Bray F, et al. Global trends in colorectal cancer mortality: projections to the year 2035. Int J Cancer. 2019;144:2992–3000. [DOI] [PubMed]

161.

Choudhary H, Bordoloi D, Prakash J, Manteghi N, Padmavathi G, Monisha J, et al. Different chemosensitization approaches in gastric cancer. In: cancer cell chemoresistance and chemosensitization. Singapore: World Scientific; 2018. pp. 267–319. [DOI]

162.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. [DOI] [PubMed]

163.

Gupta SC, Kunnumakkara AB, Aggarwal S, Aggarwal BB. Inflammation, a double-edge sword for cancer and other age-related diseases. Front Immunol. 2018;9:2160. [DOI] [PubMed] [PMC]

164.

Khwairakpam AD, Monisha J, Banik K, Choudhary H, Sharma A, Bordoloi D, et al. Chemoresistance in brain cancer and different chemosensitization approaches. In: cancer cell chemoresistance and chemosensitization. Singapore: World Scientific; 2018. pp. 107–27. [DOI]

165.

Thakur KK, Bordoloi D, Prakash J, Monisha J, Roy NK, Kunnumakkara AB. Different chemosensitization approaches for the effective management of HNSCC. In: cancer cell chemoresistance and chemosensitization. Singapore: World Scientific; 2018. pp. 399–423. [DOI]

166.

Monisha J, Roy NK, Padmavathi G, Banik K, Bordoloi D, Khwairakpam AD, et al. NGAL is downregulated in oral squamous cell carcinoma and leads to increased survival, proliferation, migration and chemoresistance. Cancers (Basel). 2018;10:228. [DOI]

167.

Singh AK, Roy NK, Anip A, Banik K, Monisha J, Bordoloi D, et al. Different methods to inhibit chemoresistance in hepatocellular carcinoma. In: cancer cell chemoresistance and chemosensitization. Singapore: World Scientific; 2018. pp. 373–98. [DOI]

168.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. [DOI] [PubMed]

169.

Bordoloi D, Banik K, Padmavathi G, Vikkurthi R, Harsha C, Roy NK, et al. TIPE2 induced the proliferation, survival, and migration of lung cancer cells through modulation of Akt/mTOR/NF-kappaB signaling cascade. Biomolecules. 2019;9:836. [DOI]

170.

Bordoloi D, Banik K, Vikkurthi R, Thakur KK, Padmavathi G, Sailo BL, et al. Inflection of Akt/mTOR/STAT-3 cascade in TNF-alpha induced protein 8 mediated human lung carcinogenesis. Life Sci. 2020;262:118475. [DOI] [PubMed]

171.

Sung B, Kunnumakkara AB, Sethi G, Anand P, Guha S, Aggarwal BB. Curcumin circumventschemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model. Mol Cancer Ther. 2009;8:959–70. [DOI] [PubMed] [PMC]

172.

Thakur KK, Bolshette NB, Trandafir C, Jamdade VS, Istrate A, Gogoi R, et al. Role of toll-like receptors in multiple myeloma and recent advances. Exp Hematol. 2015;43:158–67. [DOI] [PubMed]

173.

Kurahashi N, Sasazuki S, Iwasaki M, Inoue M, Tsugane S; JPHC Study Group. Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol. 2008;167:71–7. [DOI] [PubMed]

174.

Muralimanoharan SB, Kunnumakkara AB, Shylesh B, Kulkarni KH, Haiyan X, Ming H, et al. Butanol fraction containing berberine or related compound from nexrutine inhibits NFkappaB signaling and induces apoptosis in prostate cancer cells. Prostate. 2009;69:494–504. [DOI] [PubMed] [PMC]

175.

Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, et al. Curcumin and pancreatic cancer: phase II clinical trial experience. J Clin Oncol. 2007;25 Suppl 18:4599. [DOI]

176.

Verma A, Guha S, Diagaradjane P, Kunnumakkara AB, Sanguino AM, Lopez-Berestein G, et al. Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res. 2008;14:2476–83. [DOI] [PubMed]

177.

Sailo BL, Bordoloi D, Banik K, Khwairakpam AD, Roy NK, Prakash J, et al. Therapeutic strategies for chemosensitization of renal cancer. In: cancer cell chemoresistance and chemosensitization. Singapore: World Scientific; 2018. pp. 615–39. [DOI]

178.

Kashyap MK, Kumar A, Emelianenko N, Kashyap A, Kaushik R, Huang R, et al. Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers. 2005;10:258–94. [DOI] [PubMed]

179.

Monisha J, Roy NK, Sharma A, Banik K, Padmavathi G, Bordoloi D, et al. Chemoresistance and chemosensitization in melanoma. In: cancer cell chemoresistance and chemosensitization. Singapore: World Scientific; 2018. pp. 479–527. [DOI]

180.

Linares MA, Zakaria A, Nizran P. Skin cancer. Prim Care. 2015;42:645–59. [DOI] [PubMed]

181.

Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–78. [DOI] [PubMed] [PMC]

182.

Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64:706–21. [DOI] [PubMed] [PMC]

183.

Gadhikar MA, Sciuto MR, Alves MV, Pickering CR, Osman AA, Neskey DM, et al. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther. 2013;12:1860–73. [DOI] [PubMed] [PMC]

184.

Micallef I, Baron B. Doxorubicin: an overview of the anti-cancer and chemoresistance mechanisms. Ann Clin Toxicol 2020;3:1031.

185.

Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21:440–6. [DOI] [PubMed] [PMC]

186.

Arai Y, Endo S, Miyagi N, Abe N, Miura T, Nishinaka T, et al. Structure-activity relationship of flavonoids as potent inhibitors of carbonyl reductase 1 (CBR1). Fitoterapia. 2015;101:51–6. [DOI] [PubMed]

187.

Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13:1551–69. [DOI] [PubMed] [PMC]

188.

Sara JD, Kaur J, Khodadadi R, Rehman M, Lobo R, Chakrabarti S, et al. 5-fluorouracil and cardiotoxicity: a review. Ther Adv Med Oncol. 2018;10:1758835918780140. [DOI]

189.

Khan IN, Al-Karim S, Bora RS, Chaudhary AG, Saini KS. Cancer stem cells: a challenging paradigm for designing targeted drug therapies. Drug Discov Today. 2015;20:1205–16. [DOI] [PubMed]

190.

Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011;18:18–25. [DOI] [PubMed] [PMC]

191.

Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis ofoxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002;5 Suppl 15:21–33. [DOI] [PubMed]

192.

Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21. [DOI] [PubMed]

193.

Zhang D, Yang R, Wang S, Dong Z. Paclitaxel: new uses for an old drug. Drug Des Devel Ther. 2014;8:279–84. [DOI] [PubMed] [PMC]

194.

Di Michele M, Della Corte A, Cicchillitti L, Del Boccio P, Urbani A, Ferlini C, et al. A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. Biochim Biophys Acta. 2009;1794:225–36. [DOI] [PubMed]

195.

Tang L, Wei F, Wu Y, He Y, Shi L, Xiong F, et al. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. 2018;37:87. [DOI] [PubMed] [PMC]

196.

Gong L, Zhang Y, Liu C, Zhang M, Han S. Application of radiosensitizers in cancer radiotherapy. Int J Nanomedicine. 2021;16:1083–102. [DOI] [PubMed] [PMC]

197.

Wang H, Mu X, He H, Zhang XD. Cancer radiosensitizers. Trends Pharmacol Sci. 2018;39:24–48. [DOI] [PubMed]

198.

Oronsky BT, Knox SJ, Scicinski J. Six degrees of separation: the oxygen effect in the development of radiosensitizers. Transl Oncol. 2011;4:189–98. [DOI] [PubMed] [PMC]

199.

Yao JX, Yao ZF, Li ZF, Liu YB. Radio-sensitization by Piper longumine of human breast adenoma MDA-MB-231 cells in vitro. Asian Pac J Cancer Prev. 2014;15:3211–7. [DOI] [PubMed]

200.

Yu CC, Hung SK, Liao HF, Lee CC, Lin HY, Lai HC, et al. RAD001 enhances the radiosensitivity of SCC4 oral cancer cells by inducing cell cycle arrest at the G2/M checkpoint. Anticancer Res. 2014;34:2927–35. [PubMed]

201.

Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004;6:203–8. [DOI] [PubMed]

202.

Liao HF, Kuo CD, Yang YC, Lin CP, Tai HC, Chen YY, et al. Resveratrol enhances radiosensitivity of human non-small cell lung cancer NCI-H838 cells accompanied by inhibition of nuclear factor-kappa B activation. J Radiat Res. 2005;46:387–93. [DOI] [PubMed]

203.

Kunnumakkara AB, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, Aggarwal BB, et al. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clin Cancer Res. 2008;14:2128–36. [DOI] [PubMed]

204.

Liu WL, Gao M, Tzen KY, Tsai CL, Hsu FM, Cheng AL, et al. Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinoma. Oncotarget. 2014;5:3662–72. [DOI] [PubMed] [PMC]

205.

Chen YH, Wei MF, Wang CW, Lee HW, Pan SL, Gao M, et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer. Cancer Lett. 2015;357:582–90. [DOI] [PubMed]

206.

Fofaria NM, Qhattal HS, Liu X, Srivastava SK. Nanoemulsion formulations for anti-cancer agent piplartine--characterization, toxicological, pharmacokinetics and efficacy studies. Int J Pharm. 2016;498:12–22. [DOI] [PubMed] [PMC]

207.

Venkatesan J, Alam MS, Hong EJ, Kim SK, Shim MS. Preparation of piperlongumine-loaded chitosan nanoparticles for safe and efficient cancer therapy. RSC Advances. 2016;6:79307–16. [DOI]

208.

Patel K, Chowdhury N, Doddapaneni R, Boakye CHA, Godugu C, Singh M. Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple-negative breast cancer. J Pharm Sci. 2015;104:4417–26. [DOI] [PubMed] [PMC]

209.

Bezerra DP, Pessoa C, Moraes MO, Costa-Lotufo LV, Rubio Gouvea D, Jabor VAP, et al. Sensitive method for determination of piplartine, an alkaloid amide from piper species, in rat plasma samples by liquid chromatography-tandem mass spectrometry. Química Nova. 2012;35:460–5. [DOI]

210.

Liu Y, Chang Y, Yang C, Sang Z, Yang T, Ang W, et al. Biodegradable nanoassemblies of piperlongumine display enhanced anti-angiogenesis and anti-tumor activities. Nanoscale. 2014;6:4325–37. [DOI] [PubMed]

211.

Choi DG, Venkatesan J, Shim MS. Selective anticancer therapy using pro-oxidant drug-loaded chitosan-fucoidan nanoparticles. Int J Mol Sci. 2019;20:3220. [DOI]

212.

Liu Q, Zhao D, Zhu X, Chen H, Yang Y, Xu J, et al. Coloaded nanoparticles of paclitaxel and piperlongumine for enhancing synergistic antitumor activities and reducing toxicity. J Pharm Sci. 2017;106:3066–75. [DOI] [PubMed]

213.

Lee HN, Jin HO, Park JA, Kim JH, Kim JY, Kim B, et al. Heme oxygenase-1 determines the differential response of breast cancer and normal cells to piperlongumine. Mol Cells. 2015;38:327–35. [DOI] [PubMed] [PMC]